Home › Neuroblastoma › NCT00588068
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * Neuroblastic tumors diagnosed in accordance with the International Neuroblastoma Staging System OR * Clinically suspected neuroblastic tumors. PK DRAW INCLUSION CRITERIA (FOR PK DRAWS ONLY): PK Draw Inclusion Criteria * Patients who receive naxitamab as part of their standard of care Exclusion Criteria: * None
About the study
The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and tumor growth in test tubes. Your blood, marrow, and hematopoietic stem cell samples will also be tested for tumors or leukemia cells, and your serum tested for anti-tumor antibodies.
What is being tested
- Tumor and Marrow Markers (other)
Sponsor: Memorial Sloan Kettering Cancer Center · Participants: 2,070 · Started: Sep 26, 2000
Contact the study team
- Nai-Kong Cheung, M.D., Ph.D. · Phone: 646-888-2313
- Shakeel Modak, MD · Phone: 212-639-7623
Official record on ClinicalTrials.gov — NCT00588068
Locations in the U.S.
| New York | Memorial Sloan Kettering Cancer Center, New York |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.